Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICStandard

DEXASPORIN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Standard Dose
0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview DEXASPORIN is listed in Drugs@FDA under application 064135 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML Sponsor BAUSCH AND LOMB Submission history Latest submission status date: 2023-07-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview DEXASPORIN is listed in Drugs@FDA under application 064135 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML Sponsor BAUSCH AND LOMB Submission history Latest submission status date: 2023-07-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.